Back to news

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results

Globe Newswire•16/11/2026•07:00 ET
0

Key Highlights

  • ➤High-dose LX2020 cut NSVT burden 80% and PVC burden 44% at latest assessment
  • ➤FDA open to guideline-defined NSVT as primary surrogate endpoint for accelerated approval
  • ➤Lexeo expects pivotal LX2020 study initiation in 2H 2027
  • ➤Cash, cash equivalents and investments totaled $219.1 million, funding operations into 2028
  • ➤Q3 net loss widened to $38.3 million, or $0.43 per share

Expert Statements

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics

“These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM.”

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics

“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics

“Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.”

Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias

“For families living with PKP2 arrhythmogenic cardiomyopathy, the risks and uncertainties reach far beyond the clinic and into every part of daily life.”

Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias

“Our community has waited a long time for treatments that might address the underlying cause of this disease.”

Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias

“Early results like these give ACM families reason to hope for better, more targeted care.”

Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias

“We look forward to larger studies that build on these findings.”

Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment

LX2020 generally well tolerated across 10 participants with no clinically significant complement activation

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in